This study looked at men with high-risk localized prostate cancer who were treated with hormone therapy plus chemotherapy (docetaxel and estramustine) or hormone therapy alone. The main goal was to see how long patients went without their cancer coming back (relapse-free survival). However, the researchers also wanted to understand what happens after the cancer first starts to progress.
They found that the time it took for a patient's PSA to rise (biochemical progression) was a strong predictor of future problems. Men who had a longer time before their PSA increased were much less likely to have a second event, such as the cancer spreading to other parts of the body. Specifically, the risk of a second event was about half for those with a longer time to progression.
This information can help doctors and patients understand what to expect after initial treatment. It suggests that patients who have a longer period without their cancer worsening may have a better outlook. However, this is an observation from the study, not a proven effect of the treatment itself.
The study was a phase 3 clinical trial, which is a high-quality type of research. But the main findings here come from secondary analyses, so they should be interpreted with caution. The results do not change the standard treatment recommendations, but they provide useful information for monitoring patients after treatment.